Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581326 | 0.87 | ALDH1A1 (0.47) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3575638 | 0.82 | VEGFA (0.43) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3584270 | 0.81 | THRB (0.46) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3577941 | 0.79 | SCN9A (0.50) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3588997 | 0.78 | UBE2N (0.44) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3587068 | 0.78 | SCN9A (0.40) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL1784121 | 0.76 | MGLL (0.46) | ALDH1A1TP53TSHRGAAADORA3 | |
| SCHEMBL3573435 | 0.76 | THRB (0.43) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3588563 | 0.76 | UBE2N (0.44) | ALDH1A1TP53LMNAMAPTTSHR | |
| SCHEMBL3590305 | 0.75 | SCN9A (0.41) | ALDH1A1TP53LMNAMAPTSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104670-B3 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2104670-B1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-02-17 | — | — | EP | disclosed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2662366-A1 | Novel triazinedione derivatives as GABA-B receptor modulators | ADDEX Pharma S.A. (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-2104670-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | Addex Pharma SA (CH) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008056257-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMA S.A (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ALDH1A1 3515/4885TP53 4865/4885LMNA 3784/4885 |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ALDH1A1 3515/4885TP53 4865/4885LMNA 3784/4885 |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ALDH1A1 3515/4885TP53 4865/4885LMNA 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.